Largest biotech companies by revenue
Everything the company sold in its latest fiscal year, before any cost is taken off.
Amgen leads the 21 biotech companies ranked by revenue, at CHF 31B, ahead of Gilead Sciences (CHF 24.8B) and Biogen (CHF 8.3B). Figures as of 18 Nov 2026, 21:57 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 21
- First
- AmgenCHF 31B
- Median
- CHF 1B
- Combined market value
- CHF 705.3B
- Countries
- 5
- Not ranked
- 3no revenue on file
Market values as of .
All countries▾
All sectors▾
Biotech▾
| # | Company | Revenue ↓ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | AmgenAMGN · Health Care | CHF 31B | CHF 202.5B | CHF 374.28 | 3.07% down | 34% up | ||
| 2 | Gilead SciencesGILD · Health Care | CHF 24.8B | CHF 176.7B | CHF 142.48 | 0.75% down | 33% up | ||
| 3 | BiogenBIIB · Health Care | CHF 8.3B | CHF 31.3B | CHF 211.99 | 0.25% up | 49% up | ||
| 4 | argenxARGX · Health Care | CHF 3.5B | CHF 49.9B | CHF 793.65 | 0.66% down | 4% up | ||
| 5 | BioNTechBNTX · Health Care | CHF 2.7B | CHF 17.4B | CHF 70.20 | 1.89% down | 16% down | ||
| 6 | Neurocrine BiosciencesNBIX · Health Care | CHF 2.4B | CHF 13.9B | CHF 137.32 | 1.84% down | 20% up | ||
| 7 | ExelixisEXEL · Health Care | CHF 2B | CHF 14.1B | CHF 57.58 | 0.31% down | 63% up | ||
| 8 | QiagenQGEN · Health Care | CHF 1.8B | CHF 8.6B | CHF 41.79 | 0.38% down | 12% up | ||
| 9 | ModernaMRNA · Health Care | CHF 1.6B | CHF 67.1B | CHF 165.93 | 4.84% down | 755% up | ||
| 10 | Halozyme TherapeuticsHALO · Health Care | CHF 1.2B | CHF 9.2B | CHF 80.78 | 0.18% down | 37% up | ||
| 11 | Bio-TechneTECH · Health Care | CHF 1B | CHF 9.6B | CHF 61.34 | 0.17% up | 26% up | ||
| 12 | RepligenRGEN · Health Care | CHF 622.5M | CHF 9.3B | CHF 145.59 | 6.47% up | 5% up | ||
| 13 | Krystal BiotechKRYS · Health Care | CHF 328.1M | CHF 7.9B | CHF 265.89 | 5.62% up | 46% up | ||
| 14 | Twist BioscienceTWST · Health Care | CHF 317.5M | CHF 6.7B | CHF 98.11 | 3.88% up | 340% up | ||
| 15 | Adaptive BiotechnologiesADPT · Health Care | CHF 233.5M | CHF 3.9B | CHF 24.00 | 0.11% down | 88% up | ||
| 16 | ImmunityBioIBRX · Health Care | CHF 95.5M | CHF 6B | CHF 5.65 | 7.03% up | 193% up | ||
| 17 | Kymera TherapeuticsKYMR · Health Care | CHF 33.1M | CHF 8.7B | CHF 102.14 | 0.32% down | 87% up | ||
| 18 | CG OncologyCGON · Health Care | CHF 3.4M | CHF 6B | CHF 67.46 | 1.34% up | 85% up | ||
| 19 | CRISPR TherapeuticsCRSP · Health Care | CHF 3M | CHF 3.3B | CHF 33.89 | 0.10% up | 21% down | ||
| 20 | Revolution MedicinesRVMD · Health Care | CHF 0 | CHF 29.1B | CHF 134.76 | 1.76% down | 131% up | ||
| 21 | Scholar Rock HoldingSRRK · Health Care | CHF 0 | CHF 4.9B | CHF 40.47 | 6.48% up | 14% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration; annual figures from the reports companies file with the SEC.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Revenue is from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day, not of the period. Sums are converted from US dollars at today's exchange rate (1 USD = 0.8432 CHF). 3 companies have no revenue on file and are not ranked here.
Questions and answers
Which biotech companies rank first by revenue?
Amgen (CHF 31B), Gilead Sciences (CHF 24.8B) and Biogen (CHF 8.3B) are the top three of the 21 biotech companies ranked by revenue as of 18 Nov 2026, 21:57 UTC.
How many biotech companies are in this ranking?
21 are ranked by revenue. 3 more have no revenue on file and are left out rather than ranked at zero.
What are these biotech companies worth together?
The 21 biotech companies ranked by revenue have a combined market value of CHF 705.3B as of 18 Nov 2026, 21:57 UTC.
What does ranking by revenue measure?
Everything the company sold in its latest fiscal year, before any cost is taken off.
Learn how this ranking works
All markets guides →- Revenue vs earnings vs free cash flow: what each tells you
Revenue is everything a company sold in a period. Earnings, or net income, is what remains after every cost, interest and tax. Free cash flow is the cash operations brought in minus spending on long-lived assets. Revenue shows size and demand, earnings show profitability, and free cash flow shows how much cash the business can actually hand out.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
- How companies are sorted into sectors and industries
Companies are sorted into sectors and industries by classification systems. The index providers MSCI and S&P Dow Jones Indices use GICS: 11 sectors split into 25 industry groups, 74 industries and 163 sub-industries. SEC filings carry a four-digit SIC code. The two can place one company differently, because each looks at the business from its own angle.
Cite this page
Funkfolio, “Largest biotech companies by revenue”, data as of 18 November 2026. https://funkfolio.com/companies/category/biotech?by=revenue
Underlying data: Yahoo Finance; SEC EDGAR.